insights_auto
Why is 084990 up 14.83%?
Dive Deeperchevron_right
084990:KOSDAQ
Helixmith Co Ltd
â‚©4,530.00
arrow_upward
+14.83%(+585.00) 1D
Oct 8, 3:30:10 PM GMT+9 · KRW
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 084990...
Open
â‚©3,965
High
â‚©4,955
Low
â‚©3,765
Mkt. cap
201.53B
Avg. vol.
194.28K
Volume
4.22M
52-wk high
â‚©9,960
52-wk low
â‚©2,725
EPS
-â‚©35
Shares outstanding
46.09M
No. of employees
38
Open
â‚©3,965
High
â‚©4,955
Low
â‚©3,765
Mkt. cap
201.53B
Avg. vol.
194.28K
Volume
4.22M
52-wk high
â‚©9,960
52-wk low
â‚©2,725
EPS
-â‚©35
Shares outstanding
46.09M
No. of employees
38
News stories
From web sources and news partners
CNBC
·
30 minutes ago
Jim Cramer talks what lead the Dow higher while the Nasdaq sunk
TradingView
·
2 hours ago
Analyst Sets Stark S&P 500 Target For 2027
ChartMill
·
4 hours ago
Top S&P500 movers in Thursday's session
AOL.com
·
48 minutes ago
History Says Every S&P 500 Bull Market That Reached Its 4th Birthday Kept Going
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd